Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells

The prognosis for patients with relapsed or refractory high-risk neuroblastoma remains dismal and novel therapeutic options are urgently needed. The RIST treatment protocol has a multimodal metronomic therapy design combining molecular-targeted drugs (Rapamycin and Dasatinib) with chemotherapy backb...

Descripción completa

Detalles Bibliográficos
Autores principales: Waetzig, Rebecca, Matthes, Marie, Leister, Johannes, Penkivech, Gina, Heise, Tilman, Corbacioglu, Selim, Sommer, Gunhild
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738968/
https://www.ncbi.nlm.nih.gov/pubmed/33390782
http://dx.doi.org/10.7150/ijms.48393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738968/
https://www.ncbi.nlm.nih.gov/pubmed/33390782
http://dx.doi.org/10.7150/ijms.48393

Ejemplares similares